

## SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Wotalla Davis Examiner #: 78962 Date: 6-8-01  
Art Unit: 1642 Phone Number 30 8-6410 Serial Number: 09/71788  
Mail Box and Bldg/Room Location: 8E12 CM1 9809 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

\*\*\*\*\*  
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: \_\_\_\_\_

Inventors (please provide full names): \_\_\_\_\_

Earliest Priority Filing Date: 11-22-99

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search claims 1-3

RECEIVED

JUN -8 2001

STIC

## STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: _____	NA Sequence (#) _____	STN <u>101</u> <sup>60</sup>
Searcher Phone #: <u>Alex Wacławiw</u>	AA Sequence (#) _____	Dialog _____
Searcher Location: <u>Technical Info. Specialist</u>	Structure (#) _____	Questel/Orbit _____
<u>CM1-12C14 Tel: 308-4491</u>	Bibliographic <u>✓</u>	Dr. Link _____
Date Searcher Picked Up: <u>6-28-01</u>	Litigation _____	Lexis/Nexis _____
Date Completed: <u>6-28-01</u>	Fulltext _____	Sequence Systems _____
Searcher Prep & Review Time: _____	Patent Family _____	WWW/Internet _____
Clerical Prep Time: _____	Other _____	Other (specify) _____
Online Time: _____		

=&gt; d his

(FILE 'HCAPLUS' ENTERED AT 13:21:57 ON 28 JUN 2001)

DEL HIS Y

FILE MEDLINE, BIOSIS, WPI, HCAPLUS, EMBASE ENTERED AT 13:22:29 ON 28 JUN 2001

L1 1 S OVR107 OR OVR 107  
 L2 1 S (OVR107 OR OVR 107)/AB  
 L3 1 S L1 OR L2

=&gt; d all 13

L3 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2001 ACS  
 AN 2001:396694 HCAPLUS  
 TI A novel method of diagnosing, monitoring, staging, imaging and treating cancer  
 IN Salceda, Susana; Cafferkey, Robert; Lou, Xing Jian; Recipon, Herve; Sun, Yongming  
 PA Diadexus, Inc., USA  
 SO PCT Int. Appl., 33 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K039-00  
 ICS A61K048-00; A61K049-00; C07H021-02; C07H021-04; C07K014-00; C12N015-11; C12N015-63; C12P019-34; C12Q001-68; G01N033-53  
 CC 15-2 (Immunochemistry)  
 Section cross-reference(s): 1, 3, 63, 14

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001037864	A1	20010531	WO 2000-US31896	20001121
	W: CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				

PRAI US 1999-166818 P 19991122

AB The present invention provides new markers and methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating cancer. Diagnostic marker for cancer comprises **Ovr107**, and anti-**Ovr107** antibody or labeled antibody and fragments are used for imaging and monitoring cancer, as well as for identifying potential therapeutic agents. Genetic primers were used for detecting **Ovr107** mRNA expression and for diagnosing cancer and metastasis.

ST **Ovr107** cancer metastasis marker antibody primer

IT Adoptive immunotherapy

Antitumor agents

Body fluid

DNA sequences

Gene therapy

Imaging

Labels

Molecular cloning

Ovary, neoplasm

Tumor markers

- Vaccines
  - (Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)
- IT Radionuclides
  - RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
  - (Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)
- IT Molecules
  - (Ovr107-downregulating; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)
- IT Drug screening
  - (cancer therapeutic; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)
- IT Diagnosis
  - Prognosis
    - (cancer; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)
- IT Ovary, neoplasm
  - (carcinoma; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)
- IT Cytotoxic agents
  - (conjugates; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)
- IT Neoplasm
  - (diagnosis; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)
- IT Immunoglobulins
  - RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
  - (fragments; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)
- IT Paramagnetic materials
  - (label; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)
- IT Neoplasm
  - (metastasis; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)
- IT Antibodies
  - RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
  - (monoclonal; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)
- IT Antibodies
  - RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
  - (polyclonal and omniclonal; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)
- IT Animal cell
  - Animal tissue
    - (sample; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)
- IT Antigens
  - RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(tumor-assocd., **Ovr107**; **Ovr107** as marker for  
diagnosing, prognosticating, monitoring, staging, imaging and treating  
cancer)  
IT 343284-82-2 343284-83-3 343284-84-4  
RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic  
use);  
ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(**Ovr107** as marker for diagnosing, prognosticating,  
monitoring, staging, imaging and treating cancer)  
IT 343287-27-4  
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study);  
USES  
(Uses)  
(amino acid sequence; **Ovr107** as marker for diagnosing,  
prognosticating, monitoring, staging, imaging and treating cancer)  
RE.CNT 2  
RE  
(1) Bodey, B; Anticancer Research 2000, V20, P2665 HCAPLUS  
(2) Goodison, S; Histopathology 1998, V32, P1 MEDLINE

=&gt; fil reg

**FILE REGISTRY** ENTERED AT 14:10:07 ON 28 JUN 2001  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 27 JUN 2001 HIGHEST RN 343764-40-9  
 DICTIONARY FILE UPDATES: 27 JUN 2001 HIGHEST RN 343764-40-9

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT  
 for details.

=&gt; d que 12

L2 2 SEA FILE=REGISTRY ABB=ON  
~~GGGCGGCTGGGGG\*TCGGGACCC\*GCTGCTGG\*AG~~  
~~TCCTTCGGG/SQSN~~

=&gt; d 12 sqide 1-2

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2001 ACS  
 RN 343287-27-4 REGISTRY  
 CN INDEX NAME NOT YET ASSIGNED  
 FS NUCLEIC ACID SEQUENCE  
 SQL 1635  
 NA 322 a 511 c 548 g 249 t 5 n  
 NTE doublestranded

```

SEQ      1 tcgcggccgc aggagccggc gccgggcccgc tggggagggc ttgctgacgc
          =====
        51 tgcgggccaa gccgccctcg gaggccgagt acaccgacgt gctgcagaag
          =====
       101 atcaagtacg ccttcagcct gctggcccgc ctgcgcggca acatcgccga
          =====
       151 cccctcctct ccggagctgt tgcacttctt tttcgggcct ctgcagatga
          =====
       201 ttgtgaacac gtcggggggg ccggagttcg cgagcagtgt gcggcgggccg
          =====
       251 catctgacat cggatgccgt ggcgctgctg cgggacaacg tcaactccacg
          =====
       301 tgaaaacgag ctctggacct cgctggggga ctctgtgacc cgccccgggc
          =====
       351 tggagctgtc cccggaggag ggacccccat acagaccgga gttcttcagc
          =====
       401 ggctgggagc cgccggtcac tgaccgcgag agccgcgcct gggaggaccc
          =====
       451 agttgagaaa cagctacagc acgagcggag gcgccggcag caaagcgccc
          =====
       501 ccgaggtcgc tgtcaatggt caccgaggac ttgggagcca gaatctgagc
  
```

```

=====
551 ctcagctgga gtcagagaca gcaggaaaat gggtcctgtg taattatgac
=====
601 ttccaggccc gcaacagcag tgagctgtcg gtcaagcagc gggacgtact
=====
651 ggaggtcctg gatgacagtc gtaagtgggtg gaaggttcgg gacccagcgg
=====
701 ggcaggaggg atatgtgccc tacaacatcc tgacacccta ccccggaacc
=====
751 cggctgcacc acagccaaag ccctgcccgc agcctgaaca gcactcctcc
=====
801 tccaccacca gccccagccc cggccccacc tccagctctg gctcggcccc
=====
851 gctgggacag gccccgctgg gacagctgcg atanctcaac ggcttgacc
=====
901 ccagcgagaa ggagaaattc tcccagatgc tcctcgtcaa cgaggaactg
=====
951 caggcgcgcc tggcccaggg ccgctcggga ccgagccgcg cagtcccagg
=====
1001 gccccgcgcc ccggaaccgc agctcagccc gggctcggac gcctccgang
=====
1051 tccgcgcctg gctgcaggnc aagggttta gctccgggac cgtggacgcg
=====
1101 ctgggtgtgc tgaccggggc gcacttttct cgctgcagaa ggaggagctg
=====
1151 cgggcggtga gccccgagga gggggcacgt gtgtacagcc aggtcaccgt
=====
1201 gcagcgcttc gctgctggag gacaaagaga aagtgtcaga gctggaggca
=====
1251 gtgatggaga agcaaaagaa gaaggtggaa ggcgaggtgg aaatggaggt
=====
1301 catttgacct gccaggcgcc cttcgcaaag agtgacgagg ccccgaggga
=====
1351 gaacggactc ctcagactct cccaatagc ggaagtcgat cttctgaagg
=====
1401 atggccaatc tgctccggcc ctggtcttcc cccatcccgg tggacagact
=====
1451 taacgatcct tgctgcagtc cctccggaga ggatctggac tggctgggag
=====
1501 tggggagggc gtggagacag tctacggaaa gcgctagcag acccccgaga
1551 ggggtgcagt gagccctgag cattgtaata tgcggcccag cctataaaca
1601 gcctccgtgc ttagcagatg gtgtgccant tnaaa

```

HITS AT: 24-1477

MF Unspecified

CI MAN

SR CA

LC STN. Files: CAPLUS

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2001 ACS

RN 256624-37-0 REGISTRY

CN GenBank: AK000265 (9CI) (CA INDEX NAME)

FS NUCLEIC ACID SEQUENCE

SQL 2228

NA 467 a 673 c 775 g 313 t

NTE singlestranded

```

SEQ      1 agagcaagga agggcagggg acctgggaag gaagttcttg aaggcagtgg
      51 ggttttgagat tggacccagg gtcaagatag aacatgaagg tgggatgagg
     101 acatgaacag aacatggcca agaaggatct gggggagcag ccaggacgag
     151 gcggagctga tccgagagga cattcagggg gctctgcaca attaccgctc
     201 gggccgctgg gagcgcaggg cggcggcgct cagggccacg caggaggagt
     251 tgcagcgca cgcctcgccc gccgctgaga ccccgccctt gcagcgccgc
     301 ccgtcagtc gcgcagtgat cagcaccgta gagcggggcg cgggccgcgg
     351 acgaccccag gcgaagccca ttcccagggc agaggaggcg cagaggcctg
     401 agccggtggg gacctcgagc aacgctgact cggcctcccc ggacctgggt
     451 ccccggggtc ctgacctggc ggttctgcag gcggagcggg aagtggacat
     501 cctgaaccac gtgttcgacg acgtagagag ctttgtatcg aggctgcaga
     551 agtcggcgga ggcggccagg gtgctggagc accgggaacg cggccgcagg
     601 agccggcgcc gggcggtctg ggagggcttg ctgacgctgc gggccaagcc
           =====
     651 gccctcggag gccgagtaca ccgacgtgct gcagaagatc aagtacgcct
           =====
     701 tcagcctgct ggcccggctg cgcggcaaca tcgccgacct ctctctccg
           =====
     751 gagctgttgc acttcctttt cgggcctctg cagatgattg tgaacacgtc
           =====
     801 gggggggcgg gagttcgca gcagtgtgcg gcggccgcat ctgacatcgg
           =====
     851 atgccgtggc gctgctgcgg gacaacgtca ctccacgtga aaacgagctc
           =====
     901 tggacctcgc tgggggactc gtggaccgc cccgggctgg agctgtcccc
           =====
     951 ggaggaggga ccccatata gacccgagtt cttcagcggc tgggagccgc
           =====
    1001 cggtcactga cccgcagagc cgcgcctggg aggaccagt tgagaaacag
           =====
    1051 ctacagcacg agcggaggcg ccggcagcaa agcgccccc aggtcgctgt
           =====
    1101 caatggtcac cgagacttgg agccagaatc tgagcctcag ctggagtcag
           =====
    1151 agacagcagg aaaatgggtc ctgtgtaatt atgacttcca ggcccgaac
           =====
    1201 agcagtgagc tgtcgggtcaa gcagcgggac gtactggagg tcctggatga
           =====
    1251 cagtcgtaag tgggtggaag ttccgggacc agcggggcag gagggatatg
           =====
    1301 tgccctacaa catcctgaca ccctaccccg gaccccggtt gcaccacagc
           =====
    1351 caaagccctg cccgcagcct gaacagcact cctcctccac caccagcccc
           =====
    1401 agccccggcc ccacctccag ctctggctcg gccccgctgg gacaggcccc
           =====
    1451 gctgggacag ctgcgatagc ctcaacggct tggaccccag cgagaaggag
           =====
    1501 aaattctccc agatgctcat cgtcaacgag gaactgcagg cgcgcctggc
           =====
    1551 ccagggccgc tcgggaccga gccgcgcagt cccagggcc cgcgccccgg
           =====
    1601 aaccgcagct cagcccgggc tcggacgcct ccgaggtccg cgcctggctg
           =====
    1651 caggccaagg gcttttagct cgggaccgtg gacgcgctgg gtgtgctgac
           =====
    1701 cggggcgca cttttctcgc tgcagagggg ggagctgcgg gcggtgagcc

```

```

=====
1751 ccgaggaggg ggcacgtgtg tacagccagg tcatcgtgca gcgctcgctg
=====
1801 ctggaggaca aagagaaagt gtcagagctg gaggcagtga tggagaagca
=====
1851 aaagaagaag gtggaaggcg aggtggaaat ggaggtcatt tgacctgcca
=====
1901 ggcgcccttc gcaaagagtg acgaggcccc gtgggagaac ggactcctca
=====
1951 gactctcccc aatagcgga gtcgatcttc tgaaggatgg ccaatctgct
=====
2001 ccggcccttg tcttccccca tcccgcgga cagacttaac gatccttgct
=====
2051 gcagtccttc cggagaggat ctggactggc tgggagtggg gagggcgtgg
=====
2101 agacagtcta cggaaagcgc tagcagaccc ccgagagggt gcagtggagc
2151 cctgagcatt gtaatatgcg gccagccta taaacagcct ccgtgcttaa
2201 aaaaaaaaaa aaaaaaaaaa aaaaaaaa

```

HITS AT: 611-2063  
MF Unspecified  
CI MAN  
SR GenBank  
LC STN Files: GENBANK

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 14:10:30 ON 28 JUN 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 28 Jun 2001 VOL 135 ISS 1  
FILE LAST UPDATED: 27 Jun 2001 (20010627/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d his 13



(FILE 'REGISTRY' ENTERED AT 14:05:48 ON 28 JUN 2001)

FILE 'HCAPLUS' ENTERED AT 14:09:47 ON 28 JUN 2001

FILE 'REGISTRY' ENTERED AT 14:10:07 ON 28 JUN 2001

FILE 'HCAPLUS' ENTERED AT 14:10:30 ON 28 JUN 2001

=> d all

L3 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2001 ACS  
 AN 2001:396694 HCAPLUS  
 TI A novel method of diagnosing, monitoring, staging, imaging and treating cancer  
 IN Salceda, Susana; Cafferkey, Robert; Lou, Xing Jian; Recipon, Herve; Sun, Yongming  
 PA Diadexus, Inc., USA  
 SO PCT Int. Appl., 33 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K039-00  
 ICS A61K048-00; A61K049-00; C07H021-02; C07H021-04; C07K014-00; C12N015-11; C12N015-63; C12P019-34; C12Q001-68; G01N033-53  
 CC 15-2 (Immunochemistry)  
 Section cross-reference(s): 1, 3, 63, 14  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001037864	A1	20010531	WO 2000-US31896	20001121
	W: CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
PRAI	US 1999-166818	P	19991122		
AB	The present invention provides new markers and methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating cancer. Diagnostic marker for cancer comprises Ovr107, and anti-Ovr107 antibody or labeled antibody and fragments are used for imaging and monitoring cancer, as well as for identifying potential therapeutic agents. Genetic primers were used for detecting Ovr107 mRNA expression and for diagnosing cancer and metastasis.				
ST	Ovr107 cancer metastasis marker antibody primer				
IT	Adoptive immunotherapy Antitumor agents Body fluid DNA sequences Gene therapy Imaging Labels Molecular cloning Ovary, neoplasm Tumor markers Vaccines				

(Ovr107 as marker for diagnosing, prognosticating, monitoring, staging,

imaging and treating cancer)

IT Radionuclides  
 RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

IT Molecules  
 (Ovr107-downregulating; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

IT Drug screening  
 (cancer therapeutic; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

IT Diagnosis  
 Prognosis  
 (cancer; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

IT Ovary, neoplasm  
 (carcinoma; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

IT Cytotoxic agents  
 (conjugates; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

IT Neoplasm  
 (diagnosis; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

IT Immunoglobulins  
 RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (fragments; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

IT Paramagnetic materials  
 (label; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

IT Neoplasm  
 (metastasis; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

IT Antibodies  
 RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (monoclonal; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

IT Antibodies  
 RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (polyclonal and omniclonal; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

IT Animal cell  
 Animal tissue  
 (sample; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

IT Antigens  
 RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (tumor-assocd., Ovr107; Ovr107 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

Davis 09/717,883

IT 343284-82-2 343284-83-3 343284-84-4

RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use);

ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(Ovrl07 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

IT ~~343287-27-4~~

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)  
(amino acid sequence; Ovrl07 as marker for diagnosing, prognosticating, monitoring, staging, imaging and treating cancer)

RE.CNT 2

RE

- (1) Bodey, B; Anticancer Research 2000, V20, P2665 HCAPLUS
- (2) Goodison, S; Histopathology 1998, V32, P1 MEDLINE

Davis 09/717,883

=> fil reg

FILE 'REGISTRY' ENTERED AT 14:17:15 ON 28 JUN 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 27 JUN 2001 HIGHEST RN 343764-40-9  
DICTIONARY FILE UPDATES: 27 JUN 2001 HIGHEST RN 343764-40-9

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT  
for details.

=> d que 11

L1 1 SEA FILE=REGISTRY ABB=ON ~~256624-37-0~~

=> fil genbank

FILE 'GENBANK' ENTERED AT 14:17:20 ON 28 JUN 2001

GENBANK (R) IS A REGISTERED TRADEMARK OF THE U.S. DEPARTMENT  
OF HEALTH AND HUMAN SERVICES.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> d his 12

(FILE 'GENBANK' ENTERED AT 14:17:06 ON 28 JUN 2001)

~~12~~ ~~FILE 'REGISTRY' ENTERED AT 14:17:15 ON 28 JUN 2001~~

FILE 'REGISTRY' ENTERED AT 14:17:15 ON 28 JUN 2001

FILE 'GENBANK' ENTERED AT 14:17:20 ON 28 JUN 2001

=> d all

L2 ANSWER 1 OF 1 GENBANK.RTM. COPYRIGHT 2001

LOCUS (LOC): ~~AK000265~~ GenBank (R)  
~~GenBank ACC NO. (GBN): AK000265~~  
CAS REGISTRY NO. (RN): ~~256624-37-0~~  
SEQUENCE LENGTH (SQL): 2228  
MOLECULE TYPE (CI): mRNA; linear  
DIVISION CODE (CI): Primates  
DATE (DATE): 22 Feb 2000  
DEFINITION (DEF): Homo sapiens cDNA FLJ20258 fis, clone COLF7250.

KEYWORDS (ST): oligo capping; fis (full insert sequence)  
 SOURCE: Homo sapiens colon mucosa cDNA to mRNA, clone\_lib:ColF  
 clone:COLF7250.  
 ORGANISM (ORGN): Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae;  
 Homo

NUCLEIC ACID COUNT (NA): 467 a 673 c 775 g 313 t

## COMMENT:

NEDO human cDNA sequencing project supported by Ministry of  
 International Trade and Industry of Japan; cDNA full insert  
 sequencing: Research Association for Biotechnology; cDNA library  
 construction, 5'- & 3'-end one pass sequencing: Department of  
 Virology and Human Genome Center, Institute of Medical Science,  
 University of Tokyo (partly supported by Science and Technology  
 Agency).

REFERENCE: 1 (sites)  
 AUTHOR (AU): Watanabe,K.; Kumagai,A.; Itakura,S.; Yamazaki,M.;  
 Tashiro,H.; Ota,T.; Suzuki,Y.; Obayashi,M.; Nishi,T.;  
 Shibahara,T.; Tanaka,T.; Nakamura,Y.; Isogai,T.;  
 Sugano,S.  
 TITLE (TI): NEDO human cDNA sequencing project  
 JOURNAL (SO): Unpublished (2000)  
 REFERENCE: 2 (bases 1 to 2228)  
 AUTHOR (AU): Sugano,S.; Suzuki,Y.; Ota,T.; Obayashi,M.; Nishi,T.;  
 Isogai,T.; Shibahara,T.; Tanaka,T.; Nakamura,Y.  
 TITLE (TI): Direct Submission  
 JOURNAL (SO): Submitted (15-FEB-2000) to the DDBJ/EMBL/GenBank  
 databases. Sumio Sugano, Institute of Medical Science,  
 University of Tokyo, Deptment of Virology;  
 Shirokane-dai, 4-6-1, Minato-ku, Tokyo 108-8639, Japan  
 (E-mail:cdnal@ims.u-tokyo.ac.jp, Tel:81-3-5449-5286,  
 Fax:81-3-5449-5416)

## FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..2228	/organism="Homo sapiens" /db-xref="taxon:9606" /clone="COLF7250" /clone-lib="ColF" /tissue-type="colon mucosa" /note="cloning vector pME18SFL3"
CDS	103..1893	/note="unnamed protein product" /codon-start=1 /protein-id="BAA91041.1" /db-xref="GI:7020230" /translation="MNRTWPRIWGSSQDEAELI REDIQGALHNYRSGRGERRAALR ATQEELQRDRSPAETPPLQRRPSVRAVISTVER GAGRGRPQAKPIPEAEEAQRPEPV GTSSNADSASPD LGPRGPD LAVLQAEREVDILNH VFDDVESFVSRLQKSAEAAARVLEH RERGRSRRAAGEGLLT LRAKPPSEAEYTDVLQ KIKYAFSLLARLRGNIADPSSPEL LHFLFGPLQMI VNTSGGPEFASSVRRPHLTSDAV ALLRDNVTPRENELWTS LGDSWTR

PGLELSPEEGPPYRPEFFSGWEPPVTD PQSRAWE  
 DPVEKQLQHERRRRQQSAPQVAVN  
 GHRDLEPESEPOLESETAGKWVLCNYDFQARNSS  
 ELSVKQRDVLVLDLDDSRKWWKVRD  
 PAGQEGYVPYNILTPYPGPRLLHHSQSPARSLNST  
 PPPPPAPAPAPPPALARPWRDRPR  
 WDCDSLNLGLDPSEKEKFSQMLIVNEELQARLAQ  
 GRSGPSRAVPGPRAPEPQLSPGSD  
 ASEVRAWLQAKGFSSGTVDALGVLGTGAQLFSLQR  
 EELRAVSPEEGARVYSQVIVQRS  
 LEDKEKVSELEAVMEKQKKKVEGEVEMEVI"

## SEQUENCE (SEQ):

1	agagcaagga	agggcagggg	acctgggaag	gaagttctgg	aaggcagtg	ggtttgagat
61	tggacccagg	gtcaagatag	aacatgaagg	tgggatgagg	acatgaacag	aacatggcca
121	agaaggatct	gggggagcag	ccaggacgag	gcggagctga	tccgagagga	cattcagggg
181	gctctgcaca	attaccgctc	gggccgcggg	gagcgcagg	cggcggcgct	cagggccacg
241	caggaggagt	tgcagcgcga	ccgctcgccc	gccgctgaga	ccccgcccct	gcagcgccgc
301	ccgtcagtc	gcgcagtgat	cagcaccgta	gagcggggcg	cgggccgcgg	acgaccccag
361	gcgaagccca	ttcccagggc	agaggaggcg	cagaggcctg	agccggtggg	gacctcgagc
421	aacgctgact	cggcctcccc	ggacctgggt	ccccggggtc	ctgacctggc	ggttctgcag
481	gcggagcggg	aagtggacat	cctgaaccac	gtgttcgacg	acgtagagag	ctttgtatcg
541	aggctgcaga	agtcggcgga	ggcgccagg	gtgctggagc	accgggaacg	cggccgagc
601	agccggcgcc	ggcgcgctgg	ggagggcttg	ctgacgctgc	gggccaagcc	ggcctcgag
661	gccgagtaca	ccgacgtgct	gcagaagatc	aagtacgcct	tcagcctgct	ggccccggtg
721	cgcggaaca	tcgcccagcc	ctcctctccg	gagctgttgc	acttcctttt	cgggcctctg
781	cagatgattg	tgaacacgtc	ggggggggccg	gagttcgcg	gcagtggtgc	gcggccgcat
841	ctgacatcgg	atgccgtggc	gctgctgcgg	gacaacgtca	ctccacgtga	aaacgagctc
901	tggacctcgc	tgggggactc	gtggacccgc	cccgggctgg	agctgtcccc	ggaggaggga
961	ccccataca	gacccgagtt	cttcagcggc	tgggagccgc	cggctactga	cccgcagagc
1021	cgcgccctggg	aggacccagt	tgagaacacg	ctacagcacg	agcggaggcg	ccggcagcaa
1081	agcgcccccc	aggctcgctgt	caatggtcac	cgagacttgg	agccagaatc	tgagcctcag
1141	ctggagtcag	agacagcagg	aaaatgggtc	ctgtgtaatt	atgacttcca	ggccccgaac
1201	agcagtgagc	tgtcgggtcaa	gcagcgggac	gtactggagg	tcctggatga	cagtcgtaag
1261	tgggtggaagg	ttcgggaccc	agcggggcag	gagggatatg	tgccctacaa	catcctgaca
1321	ccctaccccc	gaccccggtc	gcaccacagc	caaagccctg	cccgcagcct	gaacagcact
1381	cctcctccac	caccagcccc	agccccggcc	ccacctccag	ctctggctcg	gccccgctgg
1441	gacaggcccc	gctgggacag	ctgcgatagc	ctcaacggct	tggaccccag	cgagaaggag
1501	aaattctccc	agatgctcat	cgtcaacgag	gaactgcagg	cgcgcctggc	ccagggccgc
1561	tcgggaccga	gccgcgcagt	cccaggggcc	cgcgccccgg	aaccgcagct	cagcccgggc
1621	tcggacgcct	ccgaggtccg	cgcctggctg	caggccaagg	gcttttagctc	cgggaccgtg
1681	gacgcgctgg	gtgtgctgac	cggggcgag	cttttctcgc	tgagaggga	ggagctgcgg
1741	gcggtgagcc	ccgaggagg	ggcacgtgtg	tacagccagg	tcacgtgca	gcgctcgctg
1801	ctggaggaca	aagagaaagt	gtcagagctg	gaggcagtg	tggagaagca	aaagaagaag
1861	gtggaaggcg	aggtggaaat	ggaggtcatt	tgacctgcca	ggcgcccttc	gcaaagagt
1921	acgaggcccc	gtgggagaac	ggactcctca	gactctcccc	aatagcgga	gtcgatcttc
1981	tgaaggatgg	ccaatctgct	ccggccctgg	tcttccccca	tcccggcgga	cagacttaac
2041	gacccctgct	cagtccttc	cggagaggat	ctggactggc	tgggagtg	gagggcgctg
2101	agacagtcta	cggaaagcgc	tagcagaccc	ccgagagggt	gcagtgagc	cctgagcatt
2161	gtaatatg	gcccagccta	taaacagcct	ccgtgcttaa	aaaaaaaaa	aaaaaaaaa
2221	aaaaaaaa					